nAMD
2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
2030
2031
BioTherapeutics IncIVB103 Injection（Low dose）
Clinical Trials (1)
Total enrollment: 18 patients across 1 trials
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
Start: Apr 2025Est. completion: Dec 203118 patients
Phase 1Enrolling By Invitation
Related Jobs
Associate Director, U.S. Marketing Ophthalmology HCP Field Execution
USA - Pennsylvania - North Wales (Upper Gwynedd) (Hybrid)
6d ago
$142K - $224K/yr
Associate Director, U.S. Marketing Ophthalmology HCP Field Execution
USA - Pennsylvania - North Wales (Upper Gwynedd) (Hybrid)
6d ago
$142K - $224K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.